Alnylam Pharmaceuticals (ALNY) Revenue Growth (5y) (2014 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Revenue Growth (5y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 42.39% |
| Mar 31, 2026 | 45.73% |
| Dec 31, 2025 | 46.32% |
| Sep 30, 2025 | 58.25% |
| Jun 30, 2025 | 49.40% |
| Mar 31, 2025 | -21.32% |
| Dec 31, 2024 | 52.60% |
| Sep 30, 2024 | 48.20% |
| Jun 30, 2024 | 71.32% |
| Mar 31, 2024 | 71.53% |
| Dec 31, 2023 | 83.68% |
| Sep 30, 2023 | 225.03% |
| Jun 30, 2023 | 60.52% |
| Mar 31, 2023 | 70.90% |
| Dec 31, 2022 | 54.61% |
| Sep 30, 2022 | 72.92% |
| Jun 30, 2022 | 69.79% |
| Mar 31, 2022 | 62.26% |
| Dec 31, 2021 | 71.45% |
| Sep 30, 2021 | 68.90% |